Introduction
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men, while it second only to breast cancer in women. It was estimated that 1.4 million cases and 693,900 deaths might have occurred in 2012 [@B1]. Although CRC incidence rate has been thought to be less common in Asian than that in western countries [@B2], it has been greatly increasing in recent years, and imposed a substantial economic burden in China [@B3]. CRC is a multistep process, resulting from the interaction between alterations in an individual\'s genetic profile and exposures to environmental carcinogens [@B4]. Epidemiological studies have revealed that a number of factors may contribute to the etiology of CRC, including tobacco use, lack of exercise, overweight and obesity, high consumption of red meat, and alcohol intake. The fact that only a subset of individuals exposed to risk factors actually develop CRC in their lifetime suggests that the role of genetic factors is also indispensible in the development of CRC [@B5]-[@B13].

Emerging evidence has demonstrated that DNA repair plays a critical role in maintaining genome integrity [@B14]. To date, at least five known major DNA repair pathways are validated [@B15], [@B16], among which nucleotide excision repair (NER) is the most versatile DNA repair mechanism. It is responsible for removing bulky helix-distorting DNA lesions, such as DNA adducts caused by UV radiation, mutagenic chemicals, and chemotherapeutic agents [@B17]. In humans, defects in NER pathway can result in the rare autosomal recessive disease xeroderma pigmentosum (XP), which is characterized by extreme vulnerability to UV and high susceptibility to sunlight-induced skin cancer [@B18]. Deficiencies in NER pathway were also associated with an increased risk of various types of cancer [@B19]-[@B22]. Thus far, at least seven key components (complementation groups XP-A to G) have been identified in the NER pathway [@B23].

*Xeroderma pigmentosum group G* (*XPG*), also known as *excision repair cross-complementation group 5*(*ERCC5*), is located on chromosome 13q22-q33, and encodes a 1,186-amino acid structure-specific endonuclease [@B24]. XPG is an important DNA damage recognition protein that binds to and cleaves damaged DNA at a very early stage to facilitate the downstream DNA repair process [@B25]-[@B27]. In addition, XPG has been implicated in RNA transcription through interaction with other transcription activator complexes [@B28], [@B29], which eventually influences mutagenesis and cell death [@B30]. It is widely reported that XPG is important in maintaining genomic stability and that single nucleotide polymorphisms (SNPs) in the *XPG* gene may affect XPG protein expression and function and contribute to DNA repair defects, genomic instability, which may leads to the initiation of cancer of various types [@B31], [@B32], including CRC [@B33], [@B34].

A multitude of studies have been performed to investigate the association between the *XPG* gene polymorphisms and cancer risk [@B35], including lung cancer [@B36], [@B37], gastric cancer [@B20], [@B38], [@B39], head and neck cancer [@B31], [@B40], and neuroblastoma [@B41]. However, regarding the association with CRC, the sample sizes in the published studies were relatively small, generally less than 1000 cases. Therefore, it is essential to precisely determine the relationship between potentially functional SNPs in *XPG* gene and CRC susceptibility with sufficient statistical power. Here, we conducted a two-stage case-control study to interrogate the association of interest in a Southern Chinese population consisting of 1,901 CRC patients and 1,976 healthy controls.

Materials and methods
=====================

Study population
----------------

We performed a two-stage case-control study. The first stage (discovery phase) was designed to discover the significant variants associated with CRC susceptibility in a Chinese population, consisting of 1,141 CRC cases and 1,173 cancer-free controls. The second stage (replication phase) was performed to confirm the results observed in the first-stage, consisting of 760 CRC cases and 803 controls. The reason why we reported this study as a two-stage case control study was that the control subjects were recruited differently. Basically, 1,173 controls included in the first stage were enrolled from Sihui city, while 803 controls included in the second stage were enrolled from individuals who receiving health screening in the First Affiliated Hospital of Sun Yat-sen University. Overall, we recruited CRC cases and healthy controls mainly from January 2000 to May 2010 [@B42], [@B43]. Briefly, all the research objects were unrelated ethnic Han Chinese population from Southern China. A total of 1,901 patients with CRC were enrolled from Sun Yat-sen University Cancer Center. Cases were eligible if they had histologically confirmed adenocarcinoma of the colon; patients with metastasized cancer from other organs were excluded from the study. All the cases were sporadic CRC patients without family history of CRC, familial adenomatous polyposis syndrome, or hereditary non-polyposis colorectal cancer. All 1,976 healthy controls were randomly selected in the same region, and were frequency-matched to cases by sex. After the written informed consent was obtained from a participant, we conducted a face-to-face interview using a self-administered questionnaire including demographic characteristics (e.g., age and sex), lifestyle habits (e.g., smoking habits and alcohol drinking), as well as family history of cancer. The definition of the smoking status and drinking status has been described elsewhere [@B38]. With the permission of the subjects, about 5 ml of venous blood sample was collected from each subject after interview. In general, the response rate of cases and controls was more than 80%. The experimental and research protocols were approved by the Institutional Review Board of Sun Yat-sen University Cancer Center, and all experiments on humans samples were performed in accordance with relevant guidelines and regulations.

Identification of candidate SNPs
--------------------------------

The potentially functional SNPs were selected as we described previously [@B38]. Briefly, we searched the candidate SNPs located in the 5\'- flanking region, exon, 5\'- untranslated region (5\' UTR), and 3\' UTR, which might affect transcription activity and the microRNA binding site activity. The widely reported SNP rs17655 G\>C was excluded because of its highly linkage disequilibrium (LD) with rs873601 G\>A (R^2^=0.91). As a result, five potential functional SNPs (rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C, rs1047768 T\>C and rs873601 G\>A) with a minor allele frequency (MAF) \> 5% for Chinese Han were selected. All of these five polymorphisms were not identified by previous genome-wide association studies. There was no significant LD among these polymorphisms (R^2^\<0.8). The basic parameters including location and putative function of the five selected SNPs in this study were summarized in **Supplemental Table [1](#SM1){ref-type="supplementary-material"}**.

Genotyping
----------

Genomic DNA was extracted from blood samples using the Qiagen Blood DNA Mini Kit (Qiagen Inc., Valencia, CA) following standard procedures. Genotype analyses of all SNPs were done using Taqman assays from Applied Biosystems (Foster City, CA). To obtain a high accuracy rate of genotyping results, we applied strict quality control procedures, four duplicated positive controls and four negative controls without DNA were used in each of 384-well plates. Additionally, 5% of the samples were randomly chosen for repeatedly genotyping, and 100% concordant results were obtained for all SNPs [@B38].

Statistical analysis
--------------------

Differences in distributions of covariates such as demographic characteristics, smoking and alcohol status, tumor sites, tumor stages, and the genotype frequency distributions of *XPG* polymorphism among cases and controls were compared using chi-square test. Goodness-of-fit *χ^2^* test was used to test whether the genotype frequency distribution of each polymorphism in controls was in Hardy-Weinberg equilibrium (HWE). To estimate the associations between each SNP and CRC risk, univariate and multivariate logistic regression were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Stratification analysis by age, gender, pack-years, smoking and drinking status was performed. The genotype-based mRNA expression for the three polymorphisms (rs2094258 C\>T, rs751402 C\>T, and rs873601 G\>A) were performed by a Student\'s t-test as described previously [@B38], [@B44]. All statistical analysis was performed using SAS software (version 9.1; SAS Institute, Cary, NC). All statistical tests were two-sided, and *P*\<0.05 was considered significant.

Results
=======

Population characteristics
--------------------------

The clinical and demographic characteristics of 1,901 colorectal cancer patients and 1,976 cancer-free controls were summarized in **Table [1](#T1){ref-type="table"}**. In brief, there were significant differences between the cases and controls, regarding age, smoking and alcohol status except for gender (*P=*0.518) in the first stage. Similarly, the average age of the cases was significantly higher than that of controls, while no significant difference was seen in gender (*P=*0.159) in the validation stage. The combined analysis of the first and second stages revealed that no significant differences in gender (*P=*0.174) was observed between cases and controls, while patients were significantly older than controls (57.1 ± 13.7 vs. 43.6 ± 11.9). Among CRC patients, 46.4% of lesions (882 cases) occurred in colon, and 53.6% of lesions (1,019 cases) in rectum. Regarding tumor stages, 207 (10.9%), 636 (33.5%), 609 (32.0%), and 449 cases (23.6%) had Duke stage A, B, C, and D diseases, respectively.

Associations between XPG gene polymorphisms and colorectal cancer risk
----------------------------------------------------------------------

Results were summarized in **Table [2](#T2){ref-type="table"},**including the allele frequency and genotype distribution of the selected *XPG* gene polymorphisms in CRC patients and controls, and ORs and 95% CIs. Genotype frequency distributions of all the SNPs were in HWE within the control subjects (*P=*0.623 for rs2094258, *P=*0.537 for rs751402, *P=*0.182 for rs2296147, *P=*0.875 for rs1047768, and *P=*0.875 for rs873601). A single locus analysis showed that in the first phase, the rs2094258 C\>T, rs751402 C\>T, and rs873601 G\>A polymorphisms were significantly associated with CRC susceptibility. The association between all these five polymorphisms and CRC risk were validated in the second stage. Interestingly, the significant associations became even more conspicuous after merging subjects from the two stages. While all subjects from two stages were combined, logistic regression analyses, after adjustment for age, gender, smoking and drinking status, revealed that the rs2094258 T allele was associated with the increased risk of CRC (Adjusted OR=1.17, 95% CI=1.01-1.36, *P=*0.043 for CT vs. CC; Adjusted OR=1.49, 95% CI=1.18-1.89, *P=*0.001 for TT vs. CC; Adjusted OR=1.38, 95% CI=1.10-1.72, *P=*0.005 for TT vs. CC/CT). The risk effect on CRC was also observed for the rs873601 A allele (Adjusted OR=1.18, 95% CI=1.00-1.40, *P=*0.055 for AG vs. GG; Adjusted OR=1.41, 95% CI=1.15-1.72, *P=*0.001 for AA vs. GG; and Adjusted OR=1.26, 95% CI=1.06-1.49, *P=*0.008 for AA vs. GG/AG). On the contrary, the association in the reverse direction was found between the rs751402 T allele and the risk of CRC (Adjusted OR=0.82, 95% CI=0.70-0.96, *P=*0.013 for CT vs. CC; Adjusted OR=0.69, 95% CI=0.55-0.86, *P=*0.001 for TT vs. CC; and Adjusted OR=0.77, 95% CI=0.63-0.94, *P=*0.011 for TT vs. CC/CT). No significant association was observed between CRC risk and rs2296147 T\>C polymorphism as well as the rs1047768 T\>C polymorphism.

Stratification analysis for the three significant polymorphisms
---------------------------------------------------------------

We further investigated the association between rs2094258 C\>T, rs751402 C\>T, and rs873601 G\>A polymorphisms and CRC risk in the stratified study by age, gender, smoking status, pack-year, drinking status, tumor sites, and Duke stages. The results of the first phase were shown in **Table [3](#T3){ref-type="table"}**. We found that the rs2094258 TT genotype was associated with a significantly increased risk of CRC risk among men (Adjusted OR=1.54, 95% CI=1.06-2.23), heavy cigarette smokers (Adjusted OR=2.57, 95% CI=1.13-5.85), patients with colon cancer (Adjusted OR=1.48, 95% CI=1.03-2.12), and Duke stages C+D patients (Adjusted OR=1.56, 95% CI=1.13-2.15), when CC/CT genotypes were served as a reference group. Moreover, the rs873601 AA genotype was found to be associated with a significantly increased risk of CRC among women (Adjusted OR=1.47, 95% CI=1.03-2.11), non-smokers (Adjusted OR=1.42, 95% CI=1.07-1.89), never-drinkers (Adjusted OR=1.36, 95% CI=1.05-1.77), patients with colon cancer (Adjusted OR=1.48, 95% CI=1.12-1.95) and Duke stages C+D diseases (Adjusted OR=1.53, 95% CI=1.19-1.95), when GG/AG genotypes were considered as a reference group. In contrast, we found that the rs751402 TT genotype helped to protect against CRC among the young group (Adjusted OR=0.66, 95% CI=0.48-0.90), men (Adjusted OR=0.65, 95% CI=0.47-0.90), smokers (Adjusted OR=0.59, 95% CI=0.37-0.93), patients with rectal cancer (Adjusted OR=0.73, 95% CI=0.53-0.99) and Duke stages C+D diseases (Adjusted OR=0.72, 95% CI=0.53-0.98), when compared with CC/CT genotypes.

To further validate the association of the above SNPs with predisposition to CRC, we carried out the stratified analyses of rs2094258 C\>T, rs751402 C\>T, and rs873601G\>A, using the combined sample (**Table [4](#T4){ref-type="table"}**). With the increased number of sample, we found that the significant association with the rs2094258 TT genotype became stronger in men and patients with Duke stages C+D diseases, and became weaker in subgroups divided by age and tumor site, when CC/CT genotypes were used as a reference group. The protective effect of rs751402 TT genotype became stronger in the young group and men, and was weakened in subgroups divided by tumor stage and tumor site. Finally, the risk effect of the rs873601 AA genotype was more evident in the young group, women, colon cancer, and Duke stages C+D subgroups, when GG/AG were used as control genotypes.

The correlation between genotypes of*XPG* polymorphisms and mRNA expression were shown in **Supplemental Table [2](#SM1){ref-type="supplementary-material"}.** We found significant correlation between alterations in the mRNA expression and all the three noteworthy polymorphisms, to different extents.

Discussion
==========

In the present study, we performed a two-stage case-control study to investigate the associations between five potentially functional SNPs in the *XPG* gene and CRC susceptibility in a Chinese Han population from Southern China. We identified three SNPs (rs2094258 C\>T, rs751402 C\>T and rs873601 G\>A) that were associated with CRC susceptibility (first stage), and further validated these findings in a separate case-control study (second study). To the best of our knowledge, by far, the present study is the largest investigation to explore the association of *XPG* gene polymorphisms with CRC risk.

XPG acts as an endonuclease to participate in two incision steps in NER pathway, dysfunction of which leads to the excision repair deficiency [@B45], [@B46]. XPG cleaves the DNA strand at the 3\' side of the damaged site, and stabilizes the DNA repair complex to the damaged DNA with ERCC1/XPF complex by making 5\' incision [@B47]-[@B50]. Many *XPG* gene polymorphisms can change the ability of the encoded enzyme to repair the DNA damage. Genetic variants may modulate susceptibility to colorectal cancer through complex gene-gene and gene-environment interactions [@B51], [@B52].

Although a few studies have investigated the role of *XPG* gene polymorphisms in the CRC risk, most of them were focused on *XPG* Asp1104His (rs17655 G\>C) polymorphism. In a hospital-based case-control study consisting of 532 cases and 532 controls from the Czech population, a trend towards an increased risk of CRC was found among carriers of*XPG* Asp1104His variant alleles [@B53]. Mort *et a*l. [@B54] reported that no significant association was found between *XPG* Asp1104His and CRC risk. Such null association was also observed in 79 CRC patients and 247 healthy controls in Turkish population [@B55]. In contrast, other studies reported opposite results regarding the association. In a Poland case-control study including 758 patients with CRC and 1,841 healthy controls, the *XPG* Asp1104His was significantly associated with an increased CRC risk in heterozygotes (GC genotypes) [@B34]. Liu *et al*. [@B56] found that heterozygotes and variant homozygotes of *XPG* Asp1104His had an increased risk for developing CRC in a population-based case-control study involving 1,028 CRC cases and 1,085 controls in the Chinese population. And the same study indicated that this SNP also conferred a significantly decreased progression-free survival after oxaliplatin-based adjuvant chemotherapy in CRC patients. More recently, Du *et al*. [@B57] found that *XPG* Asp1104His polymorphism was associated with a significantly increased CRC risk, especially in Asians.

In this study, we chose four SNPs (rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C, and rs873601 G\>A) located at the two ends of the *XPG* gene, and one SNP (rs1047768 T\>C) in the coding region. Overall, rs2094258 C\>T and rs873601 G\>A were shown to significantly increase CRC risk, whereas rs751402 C\>T significantly reduce the CRC risk. In a previous study, we also found that the presence of rs873601A variant genotypes was associated with a significantly elevated risk of gastric cancer in an Eastern Chinese population [@B38]. Stratification analysis of participants in the two stages suggested that male carriers of rs2094258 TT genotype showed increased CRC risk and CRC patients carrying the rs2094258 TT genotype was significantly more likely to be diagnosed with the late stages of disease (Dukes C+D). We also found that rs751402 TT genotype had a protective effect against CRC in the younger subjects and men. Finally, significant associations between rs873601 AA genotype and increased CRC risk were observed in the young group and women; moreover, subjects with rs873601 AA genotype tended to develop colon cancer and have Duke stages C/D diseases. In order to provide biological evidence for our findings from observational study, we performed genotype-based mRNA expression analysis using the HapMap data and found that all of these three significant polymorphisms can alter the *XPG* mRNA expression, to some extent. However, the precise mechanism for the association of 2094258 C\>T, rs751402 C\>T, and rs873601 G\>A polymorphisms with CRC remains unclear, because of lacking of direct functional data for these polymorphisms. Our mechanistic study based on bioinformatics analyses was informative, but quite preliminary. Besides, CRC is a complex condition caused by the interplay of environmental and genetic factors. Therefore, additional mechanistic studies are needed to unravel the molecular mechanisms underlying these observed associations.

Although we extensively analyzed five potentially functional SNPs in the *XPG* gene by adopting a large two-stage case-control study, followed by genotype-based mRNA expression analysis, there still exists some limitations to be addressed. First, frequency matching between cases and controls was only performed on gender, but not on age (± 5 year), smoking and drinking status. Multivariate logistic regression analysis was used to reduce the impact of these factors, to some extent. Second, the number of the selected *XPG* polymorphisms is limited, because this research focused on the potentially functional SNPs loci not covered by the GWAS chip analysis. As a result, some nonfunctional, low-frequency SNPs and the chain with the selected sites SNPs loci, which may also contribute to CRC susceptibility, were not included in this study. For instance, rs17655 G\>C, which was in strong LD with rs873601 G\>A, was not selected. The selected sites were also limited, which restricted further haplotypes analysis. Third, the inherent limitation of retrospective study, to a certain extent, reduced the credibility of the assessment of the CRC risk. Many other related factors such as BMI, eating habits, occupational exposure and environmental factors should be considered, since colorectal cancer is a heterogeneous disease. Forth, our study was a case-control study with subjects from Southern China, and this population may not well represent other Chinese populations in the different regions. Finally, in this hospital-based case-control study, patients were recruited from hospitals while controls were from the community. As a result, selection bias and information bias may exist. The phenomenon that the controls were more likely to be smokers and drinkers compared to the CRC group in our study may be the results of selection bias. Moreover, it should be noted that the mean age of the CRC patients was quite low in this study.

In conclusion, we found the*XPG* rs2094258 C\>T, rs751402 C\>T and rs873601 G\>A polymorphisms were associated with CRC susceptibility. Future well-designed, prospective studies with larger sample size, involving different ethnicities, are warranted to confirm our findings.
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CRC

:   colorectal cancer

NER

:   nucleotide excision repair

XP

:   xeroderma pigmentosum

XPG

:   xeroderma pigmentosum group G

ERCC5

:   excision repair cross-complementation group 5

SNP

:   single nucleotide polymorphisms

MAF

:   minor allele frequency

HWE

:   Hardy-Weinberg equilibrium

OR

:   odds ratio

CI

:   confidence interval

LD

:   linkage disequilibrium.

###### 

Clinical and demographic characteristics of colorectal cancer patients and cancer-free controls.

  Variables         Study 1       Study 2        Combined                                                                        
  ----------------- ------------- -------------- ---------- ------------- ------------- ---------- -------------- -------------- ----------
  All subjects      1141(100.0)   1173 (100.0)              760 (100.0)   803 (100.0)              1901 (100.0)   1976 (100.0)   
  Gender                                                                                                                         
  Males             753 (66.0)    789 (67.3)     0.518      397 (52.2)    448 (55.8)    0.159      1150 (60.5)    1238 (62.6)    0.174
  Females           388 (34.0)    384 (32.7)                363 (47.8)    355 (44.2)               751 (39.5)     739 (37.4)     
  Age, yr           13-89         16-80                     21-91         17-80                    13-91          16-80          
  Mean              55.7 ± 13.7   45.2 ± 11.6               59.0 ± 13.6   41.3 ± 12.1              57.1 ± 13.7    43.6 ± 11.9    
  ≤ 50              367 (32.2)    789 (67.3)     \<0.0001   193 (25.4)    594 (74.0)    \<0.0001   560 (29.5)     1383 (70.0)    \<0.0001
  51-60             342 (30.0)    285 (24.3)                190 (25.0)    180 (22.4)               532 (28.0)     466 (23.6)     
  61-70             273 (23.9)    73 (6.2)                  205 (27.0)    25 (3.1)                 478 (25.1)     98 (5.0)       
  \>70              159 (13.9)    26 (2.2)                  172 (22.6)    4 (0.5)                  331 (17.4)     30 (1.5)       
  Smoking status                                                                                                                 
  Never             830 (72.7)    662 (56.4)     \<0.0001   566 (73.7)    \-                       1396 (73.4)    \-             
  Ever              311 (27.3)    511 (43.6)                194 (26.3)    \-                       505 (26.6)     \-             
  Drinking status                                                                                                                
  No                968 (84.8)    600 (51.2)     \<0.0001   651 (85.7)    \-                       1619 (85.2)    \-             
  Yes               173 (15.2)    573 (48.8)                109 (14.3)    \-                       282 (14.8)     \-             
  Pack-years                                                                                                                     
  0                 830 (72.7)    662 (56.4)     \<0.0001   566 (73.7)    \-                       1396 (73.4)    \-             
  ≤ 30              207 (18.1)    383 (32.7)                138 (18.2)    \-                       345 (18.2)     \-             
  \> 30             104 (9.1)     128 (10.9)                56 (7.4)      \-                       160 (8.4)      \-             
  Tumor sites                                                                                                                    
  Colon             505 (44.3)    \-                        377 (49.6)    \-                       882 (46.4)     \-             
  Rectal            636 (55.7)    \-                        383 (50.4)    \-                       1019 (53.6)    \-             
  Duke Stages                                                                                                                    
  A                 130 (11.4)    \-                        77 (10.1)     \-                       207 (10.9)     \-             
  B                 363 (31.8)    \-                        273 (35.9)    \-                       636 (33.5)     \-             
  C                 359 (31.5)    \-                        250 (32.9)    \-                       609 (32.0)     \-             
  D                 289 (25.3)    \-                        160 (21.1)    \-                       449 (23.6)     \-             

^a^ Two-sided *χ*^2^ test for frequency distributions between colorectal cancer cases and cancer-free controls.

###### 

The associations between *XPG*gene polymorphisms and colorectal cancer risk.

                   Study 1      Study 2                Combined                                                                                                                                                                                                   
  ---------------- ------------ ---------------------- ----------- ---------------------- ----------- ------------ ---------------------- ----------- ---------------------- ----------- ------------- ---------------------- ------------ ---------------------- -----------
  rs2094258 C\>T                                                                                                                                                                                                                                                  
  CC               472 (41.4)   527 (44.9)                         1.00                               325 (42.8)   372 (46.3)                         1.00                               797 (41.9)    899 (45.5)                          1.00                   
  CT               522 (45.8)   524 (44.7)                         1.14 (0.93-1.39)       0.202       334 (44.0)   356 (44.3)                         1.22 (0.94-1.58)       0.135       856 (45.0)    881 (44.6)                          1.17 (1.01-1.36)       0.043
  TT               147 (12.9)   122 (10.4)                         1.44 (1.06-1.95)       0.021       101 (13.3)   75 (9.3)                           1.61 (1.08-2.40)       0.020       248 (13.1)    197 (10.0)                          **1.49 (1.18-1.89)**   **0.001**
  Additive         0.086        1.18 (1.03-1.35)       0.020                                          0.038        1.25 (1.05-1.50)       0.015                                          0.004         **1.20 (1.08-1.34)**   **0.001**                           
  Recessive        147 (12.9)   122 (10.4)             0.063       1.34 (1.01-1.80)       0.046       101 (13.3)   75 (9.3)               0.014       1.48 (1.00-2.13)       0.051       248 (13.1)    197 (10.0)             0.003        **1.38 (1.10-1.72)**   **0.005**
  rs751402 C\>T                                                                                                                                                                                                                                                   
  CC               466 (40.9)   433 (36.9)                         1.00                               326 (42.9)   290 (36.1)                         1.00                               792 (41.7)    724 (36.6)                          1.00                   
  CT               524 (46.0)   551 (47.0)                         0.88 (0.72-1.08)       0.221       336 (44.2)   401 (49.9)                         **0.71 (0.54-0.92)**   **0.010**   860 (45.3)    952 (48.2)                          0.82 (0.70-0.96)       0.013
  TT               150 (13.2)   189 (16.1)                         **0.66 (0.50-0.88)**   **0.005**   98 (12.9)    112 (13.9)                         0.63 (0.43-0.92)       0.018       248 (13.1)    301 (15.2)                          **0.69 (0.55-0.86)**   **0.001**
  Additive         0.052        **0.83 (0.73-0.95)**   **0.006**                                      0.023        **0.77 (0.64-0.92)**   **0.004**                                      0.004         **0.83 (0.75-0.92)**   **0.0004**                          
  Recessive        150 (13.2)   189 (16.1)             0.045       **0.71 (0.55-0.92)**   **0.010**   98 (12.9)    112 (13.9)             0.542       0.76 (0.53-1.08)       0.128       248 (13.1)    301 (15.2)             0.052        0.77 (0.63-0.94)       0.011
  rs2296147 T\>C                                                                                                                                                                                                                                                  
  TT               714 (62.6)   746(63.6)                          1.00                               455 (59.9)   467(58.2)                          1.00                               1169 (61.5)   1213(61.4)                          1.00                   
  CT               379 (33.2)   388 (33.1)                         1.12 (0.92-1.37)       0.260       265 (34.9)   303 (37.7)                         0.93 (0.72-1.21)       0.595       644 (33.9)    692 (35.0)                          1.01 (0.86-1.17)       0.951
  CC               48 (4.2)     39 (3.3)                           1.33 (0.81-2.17)       0.264       40 (5.3)     33 (4.1)                           1.66 (0.90-3.05)       0.102       88 (4.6)      72 (3.6)                            1.34 (0.92-1.93)       0.124
  Additive         0.523        1.13 (0.96-1.34)       0.140                                          0.335        1.06 (0.86-1.31)       0.568                                          0.266         1.06 (0.94-1.20)       0.353                               
  Recessive        48 (4.2)     39 (3.3)               0.265       1.27 (0.78-2.08)       0.332       40 (5.3)     33 (4.1)               0.280       1.71 (0.93-3.11)       0.082       88 (4.6)      72 (3.6)               0.122        1.33 (0.93-1.92)       0.122
  rs1047768 T\>C                                                                                                                                                                                                                                                  
  TT               592 (51.9)   625 (53.3)                         1.00                               378 (49.7)   398 (49.6)                         1.00                               970 (51.0)    1023 (51.7)                         1.00                   
  TC               451 (39.5)   461 (39.3)                         1.09 (0.89-1.32)       0.415       307 (40.4)   350 (43.6)                         0.99 (0.77-1.27)       0.913       758 (39.9)    812 (41.1)                          1.00 (0.86-1.16)       0.960
  CC               98 (8.6)     87 (7.4)                           1.22 (0.86-1.74)       0.267       75 (9.9)     55 (6.8)                           1.75 (1.09-2.81)       0.020       173 (9.1)     142 (7.2)                           1.33 (1.01-1.75)       0.039
  Additive         0.544        1.10 (0.95-1.27)       0.217                                          0.073        1.16 (0.96-1.41)       0.132                                          0.089         1.08 (0.97-1.21)       0.169                               
  Recessive        98 (8.6)     87 (7.4)               0.299       1.18 (0.84-1.66)       0.346       75 (9.9)     55 (6.8)               0.031       1.76 (1.11-2.79)       0.016       173 (9.1)     142 (7.2)              0.029        1.34 (1.02-1.74)       0.033
  rs873601 G\>A                                                                                                                                                                                                                                                   
  GG               266 (23.3)   323 (27.5)                         1.00                               210 (27.6)   227 (28.3)                         1.00                               476 (25.0)    550 (27.8)                          1.00                   
  AG               579 (50.7)   598 (51.0)                         1.20 (0.96-1.50)       0.112       375 (49.3)   426 (53.1)                         1.17 (0.87-1.56)       0.294       954 (50.2)    1025 (51.9)                         1.18 (1.00-1.40)       0.055
  AA               296 (25.9)   252 (21.5)                         **1.49 (1.14-1.94)**   **0.003**   175 (23.0)   150 (18.7)                         1.29 (0.91-1.83)       0.147       471 (24.8)    402 (20.3)                          **1.41 (1.15-1.72)**   **0.001**
  Additive         0.012        **1.22 (1.07-1.39)**   **0.004**                                      0.098        1.14 (0.96-1.36)       0.143                                          0.003         **1.19 (1.07-1.31)**   **0.001**                           
  Recessive        296 (25.9)   252 (21.5)             **0.012**   1.32 (1.06-1.64)       0.014       175 (23.0)   150 (18.7)             0.034       1.17 (0.87-1.56)       0.295       471 (24.8)    402 (20.3)             **0.001**    **1.26 (1.06-1.49)**   **0.008**

XPG, xeroderma pigmentosum group G; CI, confidence interval; AOR, adjusted odds ratio.

^a^*χ*^2^ test for genotype distributions between cases and controls.

^b^Adjusted for age, gender, smoking and drinking status in logistic regression models.

###### 

Stratification analysis for associations between the three *XPG*variant genotypes and colorectal cancer risk (Study 1).

  Variables         rs2094258 (cases/controls)   Adjusted OR (95% CI)   *P*^a^                 rs751402 (cases/controls)   Adjusted OR (95% CI)   *P* ^a^   rs873601 (Case/Control)   Adjusted OR (95% CI)   *P* ^a^                                    
  ----------------- ---------------------------- ---------------------- ---------------------- --------------------------- ---------------------- --------- ------------------------- ---------------------- --------- --------- ---------------------- ------------
  Median age, yr                                                                                                                                                                                                                                        
  ≤Median           520/891                      78/108                 1.18 (0.85-1.65)       0.319                       524/836                74/163    **0.66 (0.48-0.90)**      **0.009**              444/782   154/217   1.26 (0.98-1.62)       0.074
  \>Median          474/160                      69/14                  1.80 (0.97-3.32)       0.061                       466/148                76/26     0.92 (0.56-1.50)          0.723                  401/139   142/35    1.45 (0.94-2.21)       0.090
  Gender                                                                                                                                                                                                                                                
  Males             660/712                      93/77                  **1.54 (1.06-2.23)**   **0.024**                   653/655                99/134    **0.65 (0.47-0.90)**      **0.009**              576/625   177/164   **1.22 (0.92-1.62)**   **0. 167**
  Females           334/339                      54/45                  1.06 (0.66-1.68)       0.817                       337/329                51/55     0.84 (0.54-1.33)          0.463                  269/296   119/88    1.47 (1.03-2.11)       0.036
  Smoking status                                                                                                                                                                                                                                        
  Never             727/594                      103/68                 1.24 (0.85-1.81)       0.259                       715/559                114/103   0.76 (0.54-1.06)          0.105                  615/521   215/141   **1.42 (1.07-1.89)**   **0.016**
  Ever              267/457                      44/54                  **1.60 (1.00-2.56)**   **0.049**                   275/425                36/86     **0.59 (0.37-0.93)**      **0.023**              230/400   81/111    1.23 (0.85-1.77)       0.277
  Pack-years                                                                                                                                                                                                                                            
  0                 727/594                      103/68                 1.24 (0.85-1.81)       0.259                       715/559                114/103   0.76 (0.54-1.06)          0.105                  615/521   215/141   **1.42 (1.07-1.89)**   **0.016**
  ≤ 30              181/343                      26/40                  1.23 (0.68-2.20)       0.497                       181/322                26/61     0.67 (0.38-1.18)          0.167                  152/295   55/88     1.14 (0.72-1.78)       0.581
  \> 30             86/114                       18/14                  **2.57 (1.13-5.85)**   **0.024**                   94/103                 10/25     0.46 (0.21-1.04)          0.063                  78/105    26/23     1.43 (0.73-2.77)       0.296
  Drinking status                                                                                                                                                                                                                                       
  Never             845/534                      123/66                 1.30 (0.92-1.82)       0.137                       834/499                133/101   0.74 (0.55-1.00)          0.052                  715/470   253/130   **1.36 (1.05-1.77)**   **0.019**
  Ever              149/517                      24/56                  1.42 (0.78-2.57)       0.248                       156/485                17/88     0.55 (0.29-1.04)          0.067                  130/451   43/122    1.26 (0.78-2.02)       0.343
  Tumor sites                                                                                                                                                                                                                                           
  Colon             436/1051                     69/122                 **1.48 (1.03-2.12)**   **0.034**                   440/984                65/189    0.72 (0.51-1.01)          0.057                  368/921   137/252   **1.48 (1.12-1.95)**   **0.006**
  Rectal            558/1051                     78/122                 1.28 (0.91-1.79)       0.155                       550/984                85/189    **0.73 (0.53-0.99)**      **0.042**              477/921   159/252   1.18 (0.92-1.53)       0.197
  Duke stages                                                                                                                                                                                                                                           
  A+B               439/1051                     54/122                 1.06 (0.72-1.58)       0.762                       427/984                65/189    0.72 (0.51-1.03)          0.068                  379/921   114/252   1.01 (0.76-1.36)       0.928
  C+D               555/1051                     93/122                 **1.56 (1.13-2.15)**   **0.007**                   563/984                85/189    **0.72 (0.53-0.98)**      **0.035**              466/921   182/252   **1.53 (1.19-1.95)**   **0.001**

XPG, xeroderma pigmentosum group G; CI, confidence interval; OR, odds ratio.

^a^ Adjusted for age, gender, smoking and drinking status in logistic regression models.

###### 

Stratification analysis for associations between the three *XPG*variant genotypes and colorectal cancer risk (Combined).

  Variables        rs2094258 (cases/controls)   Adjusted OR (95% CI)   *P* ^a^                rs751402 (cases/controls)   Adjusted OR (95% CI)   *P* ^a^    rs873601 (Case/Control)   Adjusted OR (95% CI)   *P* ^a^                                     
  ---------------- ---------------------------- ---------------------- ---------------------- --------------------------- ---------------------- ---------- ------------------------- ---------------------- ---------- --------- ---------------------- -----------
  Median age, yr                                                                                                                                                                                                                                         
  ≤Median          854/1576                     131/180                **1.34 (1.05-1.70)**   **0.017**                   422/640                563/1116   **0.77 (0.65-0.90)**      **0.001**              731/1399   254/357   **1.35 (1.13-1.63)**   **0.001**
  \>Median         799/204                      117/17                 **1.75 (1.03-2.98)**   **0.039**                   370/84                 545/137    0.90 (0.67-1.22)          0.513                  699/176    217/45    1.21 (0.85-1.74)       0.294
  Gender                                                                                                                                                                                                                                                 
  Males            1005/1119                    145/119                **1.41 (1.06-1.88)**   **0.018**                   474/449                675/789    **0.78 (0.65-0.94)**      **0.010**              879/993    271/245   1.20 (0.97-1.50)       0\. 100
  Females          648/661                      103/78                 1.32 (0.93-1.88)       0.124                       318/275                433/464    0.80 (0.64-1.02)          0.067                  551/582    200/157   **1.34 (1.03-1.76)**   **0.031**
  Tumor sites                                                                                                                                                                                                                                            
  Colon            775/1780                     107/197                **1.40 (1.06-1.85)**   **0.020**                   362/724                520/1253   **0.80 (0.67-0.97)**      **0.020**              666/1575   216/402   **1.29 (1.04-1.59)**   **0.020**
  Rectal           878/1780                     141/197                **1.38 (1.06-1.79)**   **0.015**                   430/724                588/1253   **0.81 (0.68-0.96)**      **0.016**              764/1575   255/402   1.19 (0.97-1.45)       0.094
  Duke stages                                                                                                                                                                                                                                            
  A+B              736/1780                     107/197                1.26 (0.94-1.69)       0.123                       344/724                498/1253   **0.81 (0.67-0.98)**      **0.033**              647/1575   196/402   1.03 (0.82-1.29)       0.825
  C+D              917/1780                     141/197                **1.47 (1.14-1.90)**   **0.003**                   448/724                610/1253   **0.80 (0.68-0.95)**      **0.009**              783/1575   275/402   **1.39 (1.15-1.69)**   **0.001**

XPG, xeroderma pigmentosum group G; CI, confidence interval; OR, odds ratio.

^a^ Adjusted for age, gender, smoking and drinking status in logistic regression models.
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